350 related articles for article (PubMed ID: 22334453)
1. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?
Wong H; Yau T
Oncologist; 2012; 17(3):346-58. PubMed ID: 22334453
[TBL] [Abstract][Full Text] [Related]
2. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy in gastric cancer.
Thiel A; Ristimäki A
APMIS; 2015 May; 123(5):365-72. PubMed ID: 25706252
[TBL] [Abstract][Full Text] [Related]
4. Targeting receptor tyrosine kinases in gastric cancer.
Morishita A; Gong J; Masaki T
World J Gastroenterol; 2014 Apr; 20(16):4536-45. PubMed ID: 24782606
[TBL] [Abstract][Full Text] [Related]
5. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy in advanced gastric carcinoma: the future is beginning.
Schinzari G; Cassano A; Orlandi A; Basso M; Barone C
Curr Med Chem; 2014; 21(8):1026-38. PubMed ID: 24304282
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy for gastric cancer: Current status and future directions (Review).
Yuan DD; Zhu ZX; Zhang X; Liu J
Oncol Rep; 2016 Mar; 35(3):1245-54. PubMed ID: 26718131
[TBL] [Abstract][Full Text] [Related]
9. Molecular targeted therapy for advanced gastric cancer.
Kim JG
Korean J Intern Med; 2013 Mar; 28(2):149-55. PubMed ID: 23525404
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?
Ciliberto D; Staropoli N; Caglioti F; Gualtieri S; Fiorillo L; Chiellino S; De Angelis AM; Mendicino F; Botta C; Caraglia M; Tassone P; Tagliaferri P
Cancer Biol Ther; 2015; 16(8):1148-59. PubMed ID: 26061272
[TBL] [Abstract][Full Text] [Related]
11. [Research status quo and progression in targeted therapy for advanced gastric cancer].
Feng R; Zhang X; Yang S
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Oct; 19(10):1191-1196. PubMed ID: 27781258
[TBL] [Abstract][Full Text] [Related]
12. Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies.
Luis M; Tavares A; Carvalho LS; Lara-Santos L; Araújo A; de Mello RA
World J Gastroenterol; 2013 Oct; 19(38):6383-97. PubMed ID: 24151357
[TBL] [Abstract][Full Text] [Related]
13. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer.
Kim C; Mulder K; Spratlin J
Oncologist; 2014 Oct; 19(10):1046-55. PubMed ID: 25142842
[TBL] [Abstract][Full Text] [Related]
14. Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway.
Wilks ST
Breast; 2015 Oct; 24(5):548-55. PubMed ID: 26187798
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies in gastric cancer and future perspectives.
Yazici O; Sendur MA; Ozdemir N; Aksoy S
World J Gastroenterol; 2016 Jan; 22(2):471-89. PubMed ID: 26811601
[TBL] [Abstract][Full Text] [Related]
16. HER2 expression and PI3K-Akt pathway alterations in gastric cancer.
Sukawa Y; Yamamoto H; Nosho K; Ito M; Igarashi H; Naito T; Mitsuhashi K; Matsunaga Y; Takahashi T; Mikami M; Adachi Y; Suzuki H; Shinomura Y
Digestion; 2014; 89(1):12-7. PubMed ID: 24458107
[TBL] [Abstract][Full Text] [Related]
17. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
[TBL] [Abstract][Full Text] [Related]
18. Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review.
Kuo HY; Yeh KH
Anticancer Res; 2014 Jul; 34(7):3695-9. PubMed ID: 24982389
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives.
Roviello G; Polom K; Petrioli R; Marano L; Marrelli D; Paganini G; Savelli V; Generali D; De Franco L; Ravelli A; Roviello F
Tumour Biol; 2016 Jan; 37(1):127-40. PubMed ID: 26566626
[TBL] [Abstract][Full Text] [Related]
20. Advanced HER2-positive gastric cancer: current and future targeted therapies.
Pazo Cid RA; Antón A
Crit Rev Oncol Hematol; 2013 Mar; 85(3):350-62. PubMed ID: 23021388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
